Neovacs S.A. (ALNEV) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.129x

Based on the latest financial reports, Neovacs S.A. (ALNEV) has a cash flow conversion efficiency ratio of -0.129x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.43 Million ≈ $-2.85 Million USD) by net assets (€18.89 Million ≈ $22.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALNEV net asset quality score to measure how much of total assets are equity-financed.

Neovacs S.A. - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Neovacs S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Neovacs S.A. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Neovacs S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neovacs S.A. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Adheris Health Limited AU:AHE	-5.131x
Us1 Critical Minerals Limited AU:USC	-1.463x
Versus Systems Inc NASDAQ:VSSYW	0.007x
CuriosityStream Inc NASDAQ:CURIW	0.093x
GCM Grosvenor Inc NASDAQ:GCMGW	20.878x
RPCG PCL F F:R4Q	0.061x
European Resources Limited AU:ERE	N/A
Ordinary Fully Paid Deferred Settlement AU:CNJDG	-0.239x

Annual Cash Flow Conversion Efficiency for Neovacs S.A. (2007–2024)

The table below shows the annual cash flow conversion efficiency of Neovacs S.A. from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Neovacs S.A. worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€18.06 Million ≈ $21.12 Million	€-3.60 Million ≈ $-4.21 Million	-0.199x	-356.68%
2023-12-31	€43.82 Million ≈ $51.23 Million	€-1.91 Million ≈ $-2.24 Million	-0.044x	+56.59%
2022-12-31	€44.23 Million ≈ $51.71 Million	€-4.45 Million ≈ $-5.20 Million	-0.101x	+55.44%
2021-12-31	€43.90 Million ≈ $51.32 Million	€-9.91 Million ≈ $-11.58 Million	-0.226x	+56.14%
2020-12-31	€10.98 Million ≈ $12.84 Million	€-5.65 Million ≈ $-6.61 Million	-0.515x	+82.61%
2019-12-31	€2.74 Million ≈ $3.20 Million	€-8.10 Million ≈ $-9.47 Million	-2.958x	+45.82%
2018-12-31	€2.44 Million ≈ $2.85 Million	€-13.31 Million ≈ $-15.56 Million	-5.461x	+67.61%
2017-12-31	€845.75K ≈ $988.77K	€-14.26 Million ≈ $-16.67 Million	-16.857x	-92.46%
2016-12-31	€1.26 Million ≈ $1.47 Million	€-11.00 Million ≈ $-12.86 Million	-8.759x	-591.16%
2015-12-31	€6.07 Million ≈ $7.09 Million	€-7.69 Million ≈ $-8.99 Million	-1.267x	+12.37%
2014-12-31	€5.57 Million ≈ $6.51 Million	€-8.05 Million ≈ $-9.41 Million	-1.446x	+28.13%
2013-12-31	€3.48 Million ≈ $4.07 Million	€-7.00 Million ≈ $-8.18 Million	-2.012x	-15.00%
2012-12-31	€3.62 Million ≈ $4.23 Million	€-6.33 Million ≈ $-7.40 Million	-1.749x	-114.30%
2011-12-31	€10.57 Million ≈ $12.36 Million	€-8.63 Million ≈ $-10.09 Million	-0.816x	+16.59%
2010-12-31	€8.27 Million ≈ $9.67 Million	€-8.10 Million ≈ $-9.47 Million	-0.979x	-104.34%
2009-12-31	€-352.58K ≈ $-412.20K	€-7.95 Million ≈ $-9.29 Million	22.549x	+3373.12%
2008-12-31	€6.51 Million ≈ $7.61 Million	€-4.49 Million ≈ $-5.25 Million	-0.689x	+68.57%
2007-12-31	€1.97 Million ≈ $2.30 Million	€-4.32 Million ≈ $-5.05 Million	-2.192x	--

About Neovacs S.A.

PA:ALNEV France Biotechnology

Market Cap

$741.11K

€633.91K EUR

Market Cap Rank

#31783 Global

#600 in France

Share Price

€1.33

Change (1 day)

+3.91%

52-Week Range

€0.00 - €1.89

All Time High

€3.13